Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 89

1.

Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors.

Muller AJ, Scherle PA.

Nat Rev Cancer. 2006 Aug;6(8):613-25. Review. Erratum in: Nat Rev Cancer. 2006 Sep;6(9):742.

PMID:
16862192
[PubMed - indexed for MEDLINE]
2.

Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors.

Muller AJ, Malachowski WP, Prendergast GC.

Expert Opin Ther Targets. 2005 Aug;9(4):831-49. Review.

PMID:
16083346
[PubMed - indexed for MEDLINE]
3.

Marrying immunotherapy with chemotherapy: why say IDO?

Muller AJ, Prendergast GC.

Cancer Res. 2005 Sep 15;65(18):8065-8. Review.

PMID:
16166276
[PubMed - indexed for MEDLINE]
Free Article
4.

Targeting indoleamine 2,3-dioxygenase (IDO) to counteract tumour-induced immune dysfunction: from biochemistry to clinical development.

Rutella S, Bonanno G, De Cristofaro R.

Endocr Metab Immune Disord Drug Targets. 2009 Jun;9(2):151-77. Review.

PMID:
19519465
[PubMed - indexed for MEDLINE]
5.

A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase.

Banerjee T, Duhadaway JB, Gaspari P, Sutanto-Ward E, Munn DH, Mellor AL, Malachowski WP, Prendergast GC, Muller AJ.

Oncogene. 2008 May 1;27(20):2851-7. Epub 2007 Nov 19.

PMID:
18026137
[PubMed - indexed for MEDLINE]
6.

Indoleamine 2,3-dioxygenase in immune suppression and cancer.

Muller AJ, Prendergast GC.

Curr Cancer Drug Targets. 2007 Feb;7(1):31-40. Review.

PMID:
17305476
[PubMed - indexed for MEDLINE]
7.

The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells.

Lee SY, Choi HK, Lee KJ, Jung JY, Hur GY, Jung KH, Kim JH, Shin C, Shim JJ, In KH, Kang KH, Yoo SH.

J Immunother. 2009 Jan;32(1):22-8. doi: 10.1097/CJI.0b013e31818ac2f7.

PMID:
19307990
[PubMed - indexed for MEDLINE]
8.

Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?

Löb S, Königsrainer A, Rammensee HG, Opelz G, Terness P.

Nat Rev Cancer. 2009 Jun;9(6):445-52. doi: 10.1038/nrc2639. Review.

PMID:
19461669
[PubMed - indexed for MEDLINE]
9.

Molecular mechanisms and therapeutic reversal of immune suppression in cancer.

Gabrilovich DI.

Curr Cancer Drug Targets. 2007 Feb;7(1):1. No abstract available.

PMID:
17305473
[PubMed - indexed for MEDLINE]
10.

Highlights at the gate of tryptophan catabolism: a review on the mechanisms of activation and regulation of indoleamine 2,3-dioxygenase (IDO), a novel target in cancer disease.

Macchiarulo A, Camaioni E, Nuti R, Pellicciari R.

Amino Acids. 2009 Jul;37(2):219-29. doi: 10.1007/s00726-008-0137-3. Epub 2008 Jul 9. Review.

PMID:
18612775
[PubMed - indexed for MEDLINE]
11.

The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology.

Curti A, Trabanelli S, Salvestrini V, Baccarani M, Lemoli RM.

Blood. 2009 Mar 12;113(11):2394-401. doi: 10.1182/blood-2008-07-144485. Epub 2008 Nov 20. Review.

PMID:
19023117
[PubMed - indexed for MEDLINE]
Free Article
12.

[Immune response and cancer].

El Hage F, Abouzahr-Rifai S, Meslin F, Mami-Chouaib F, Chouaib S.

Bull Cancer. 2008 Jan;95(1):57-67. doi: 10.1684/bdc.2008.0558. Review. French.

PMID:
18230571
[PubMed - indexed for MEDLINE]
13.

Tumor immune escape mediated by indoleamine 2,3-dioxygenase.

Zamanakou M, Germenis AE, Karanikas V.

Immunol Lett. 2007 Aug 15;111(2):69-75. Epub 2007 Jul 2. Review.

PMID:
17644189
[PubMed - indexed for MEDLINE]
14.

Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.

Khawli LA, Hu P, Epstein AL.

Handb Exp Pharmacol. 2008;(181):291-328. Review.

PMID:
18071951
[PubMed - indexed for MEDLINE]
15.

High expression of indoleamine 2,3-dioxygenase gene in prostate cancer.

Feder-Mengus C, Wyler S, Hudolin T, Ruszat R, Bubendorf L, Chiarugi A, Pittelli M, Weber WP, Bachmann A, Gasser TC, Sulser T, Heberer M, Spagnoli GC, Provenzano M.

Eur J Cancer. 2008 Oct;44(15):2266-75. doi: 10.1016/j.ejca.2008.05.023. Epub 2008 Jul 9.

PMID:
18619832
[PubMed - indexed for MEDLINE]
16.

Comment on "Reduced cytotoxic function of effector CD8+ T cells is responsible for indoleamine 2,3-dioxygenase-dependent immune suppression".

Sørensen RB, thor Straten P, Andersen MH.

J Immunol. 2009 Nov 15;183(10):6040. doi: 10.4049/jimmunol.0990093. No abstract available.

PMID:
19890063
[PubMed - indexed for MEDLINE]
Free Article
17.

Targeting the immune system in cancer.

Chaudhuri D, Suriano R, Mittelman A, Tiwari RK.

Curr Pharm Biotechnol. 2009 Feb;10(2):166-84. Review.

PMID:
19199949
[PubMed - indexed for MEDLINE]
18.

The immune system--is it relevant to cancer development, progression and treatment?

Prestwich RJ, Errington F, Hatfield P, Merrick AE, Ilett EJ, Selby PJ, Melcher AA.

Clin Oncol (R Coll Radiol). 2008 Mar;20(2):101-12. Epub 2007 Nov 26. Review.

PMID:
18037277
[PubMed - indexed for MEDLINE]
19.

Reinstalling antitumor immunity by inhibiting tumor-derived immunosuppressive molecule IDO through RNA interference.

Zheng X, Koropatnick J, Li M, Zhang X, Ling F, Ren X, Hao X, Sun H, Vladau C, Franek JA, Feng B, Urquhart BL, Zhong R, Freeman DJ, Garcia B, Min WP.

J Immunol. 2006 Oct 15;177(8):5639-46.

PMID:
17015752
[PubMed - indexed for MEDLINE]
Free Article
20.

Overexpression of indoleamine 2,3-dioxygenase in human endometrial carcinoma cells induces rapid tumor growth in a mouse xenograft model.

Yoshida N, Ino K, Ishida Y, Kajiyama H, Yamamoto E, Shibata K, Terauchi M, Nawa A, Akimoto H, Takikawa O, Isobe K, Kikkawa F.

Clin Cancer Res. 2008 Nov 15;14(22):7251-9. doi: 10.1158/1078-0432.CCR-08-0991.

PMID:
19010841
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk